FDA Approved: ALUNBRIG — Original Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approves ALUNBRIG (brigatinib) under the original NDA for ALK-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)

Snippet

ORIG AP for ALUNBRIG (BRIGATINIB)